Sandoz Is First With Canadian Etanercept Indication
Sandoz has claimed a Canadian first after receiving a psoriatic arthritis indication for its Erelzi etanercept biosimilar from Health Canada.
You may also be interested in...
Merck, Sharp & Dohme’s Brenzys biosimilar version of Amgen’s Enbrel has received four new indications in Canada, bringing it in line with Sandoz’ rival biosimilar, Erelzi.
Shanghai Henlius Biotech has struck a co-development and licensing deal with fellow Chinese firm Essexor biosimilar bevacizumab to treat ophthalmic diseases.
Dr Reddy’s says it has suffered a cyber-attack and has isolated “all data center services” so that it can take actions to mitigate the impact.